TransEnterix (NYSEAMERICAN:TRXC) Stock Price Up 5.2%

Shares of TransEnterix, Inc. (NYSEAMERICAN:TRXC) rose 5.2% on Monday . The company traded as high as $1.01 and last traded at $1.01, approximately 2,999,378 shares were traded during mid-day trading. An increase of 15% from the average daily volume of 2,602,821 shares. The stock had previously closed at $0.96.

TRXC has been the subject of a number of analyst reports. Royal Bank of Canada downgraded TransEnterix from an “outperform” rating to a “sector perform” rating and set a $1.00 price target for the company. in a research note on Thursday, August 8th. BTIG Research upgraded TransEnterix from a “neutral” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Tuesday, May 14th. Piper Jaffray Companies initiated coverage on TransEnterix in a research note on Wednesday, May 22nd. They issued a “neutral” rating and a $1.60 price target for the company. Finally, Zacks Investment Research downgraded TransEnterix from a “hold” rating to a “sell” rating in a research note on Saturday, July 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. TransEnterix presently has a consensus rating of “Hold” and an average price target of $2.62.

TransEnterix (NYSEAMERICAN:TRXC) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01). The company had revenue of $3.64 million during the quarter, compared to analyst estimates of $5.13 million.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Whitnell & Co. acquired a new position in TransEnterix in the 1st quarter valued at $35,000. Geode Capital Management LLC increased its stake in shares of TransEnterix by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 1,821,799 shares of the medical instruments supplier’s stock valued at $4,117,000 after purchasing an additional 127,598 shares during the last quarter. Enterprise Bank & Trust Co bought a new position in shares of TransEnterix in the 1st quarter valued at $188,000. Virtu Financial LLC increased its stake in shares of TransEnterix by 20.0% in the 1st quarter. Virtu Financial LLC now owns 127,710 shares of the medical instruments supplier’s stock valued at $304,000 after purchasing an additional 21,269 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of TransEnterix by 36.6% in the 4th quarter. Bank of New York Mellon Corp now owns 741,871 shares of the medical instruments supplier’s stock valued at $1,677,000 after purchasing an additional 198,793 shares during the last quarter.

TransEnterix Company Profile (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

Recommended Story: Catch-Up Contributions

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.